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A prospective randomised pilot study of sedation regimens in a
general ICU population: a reality-based medicine study
Simon R Finfer, Anne M O’Connor and Malcolm M Fisher
Background: For logistical reasons sedation studies are often carried out in
elective surgical patients and the results extrapolated to the general intensive
care unit (ICU) population. We question the validity of this approach. We
compared the two sedation regimens used in our general ICU in a trial structured
to mimic clinical practice as closely as possible.
Results: Forty patients were randomised to intermittent diazepam or continuous
midazolam and sedation monitored with hourly sedation scores; 31 patients
completed the study. Scores indicating undersedation were more common with
diazepam (P<0.01); overall adequate sedation midazolam 64.7%, diazepam
35.7% (P=0.21). No patient exhibited inappropriately prolonged sedation. Cost
was: midazolam AUS$1.98/h; diazepam AUS$0.06/h.
Conclusion: Both regimens produced rapid onset of acceptable sedation but
undersedation appeared more common with the cheaper diazepam regimen. At
least 140 patients should be studied to provide evidence applicable to the
general ICU population. Used alone, a sedation score may be an inappropriate
outcome measure for a sedation trial.
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Introduction
To provide the highest quality patient care, an intensive
care unit (ICU) must constantly review treatment in
search of ‘best practice’ for that unit. The medical litera-
ture is the prime source of evidence and randomised con-
trolled trials (RCTs) are considered the gold standard for
the evaluation of competing treatments. Nevertheless,
RCTs have been criticised as strict inclusion and exclu-
sion criteria may exclude the very patients who clinicians
are obliged to treat [1]. The conduct of trials in intensive
care is further complicated by the varying case-mix
between different units so that the results of even per-
fectly conducted studies may not be relevant to a unit
with a different case-mix. As a result, it becomes neces-
sary to develop protocols and systems for examining prac-
tice in one’s own unit.
ICU sedation regimens provide a good example of the dif-
ficulty of extrapolating evidence from the literature to
one’s own practice. For logistical reasons most sedation
studies in intensive care are carried out on patients under-
going short-term sedation following elective surgical pro-
cedures. This patient population is not representative of
the population of our general ICU, making such results
inapplicable to our patients.
Two sedative regimens have evolved in our unit and the
published literature does not enable us to compare their
relative merits in our patients. We therefore set out to
compare the two regimens and, in order that our study
should produce ‘medicine-based evidence’ [2], we chose
to conduct a study that mimicked our unit’s clinical prac-
tice as closely as possible.
Sedatives are amongst the most commonly prescribed
drugs in ICUs and contribute significantly to ICU costs
[3–5]. Many agents are used and none can claim to be
ideal [5,6]. In our unit, we use intermittent intravenous
diazepam and continuous intravenous midazolam. Poten-
tial advantages of midazolam are its water solubility, its
short distribution and elimination half lives (20min and
90min, respectively)[7], and its lack of long-acting active
metabolites. In contrast diazepam has an elimination half
life of 44h [8] and its major active metabolite, desmethyl-
ICU = intensive care unit; RCT = randomised controlled trial; APACHE = Acute Physiology And Chronic Health Evaluation.diazepam, a half life of 93h [9]. These data are derived
from single dose administration to normal subjects and
much of midazolam’s pharmacokinetic advantage is lost
when administered by infusion to critically ill patients
[3,8,10]. In ICU patients, its elimination half life may be
greatly prolonged [8] and clinically important accumula-
tion may occur [11]. By using intermittent diazepam there
is a clinical disincentive to overdosage as administration of
each dose is a deliberate action by the bedside nurse. Con-
tinuous infusions of sedatives are more convenient but
risk oversedation if the infusion rate is not regularly
reduced to test the lower limit of acceptable sedation. In
terms of cost, diazepam has a clear advantage being one-
tenth the price and having twice the potency. Because of
cost and the prolonged elimination half life of midazolam
in the critically ill, our standard sedative regimen has been
intermittent intravenous diazepam, but midazolam by
continuous intravenous infusion may also be used at the
discretion of the duty ICU specialist. We set out to
compare these two regimens in our patient population in a
pilot study in 40 patients to evaluate the regimens, to
allow power calculations for future studies and to evaluate
study design.
Materials and methods
The study was approved by the Royal North Shore Hos-
pital and Community Health Services Human Research
Ethics Committee. Forty consecutive adult patients
admitted to the ICU for whom benzodiazepine sedation
was to be prescribed were entered in the study. On
admission, the patients were allocated to one of two regi-
mens by means of randomly ordered cards invisibly sealed
in gummed opaque envelopes. The regimens were either
intermittent diazepam 1–5mg by intravenous injection, or
continuous intravenous midazolam 0.05mg/kg as a loading
dose, followed by an infusion at 0.05mg/kg/h. Depth of
the sedation was monitored by the nursing sister caring
for the patient using a local modification of the Ramsay
Sedation Scale [12] (Table 1). The target sedation range
was a score in categories 1–4; category 0 was classified as
undersedation and categories 5 and 6 as oversedation.
The dose per bolus and frequency of administration of
diazepam, and the rate of midazolam infusion were
adjusted by the bedside nurse with the aim of achieving
and maintaining the level of sedation within the target
range of 1–4. Patients receiving the midazolam infusion
could receive additional bolus doses of midazolam as
required to maintain the target level of sedation. All
patients in the study received intravenous morphine as a
continuous infusion as indicated for the management of
pain. Outcome measures for the study were: time to
target range, percentage of time within target range,
percentage of time over- or undersedated; number of
patients adequately sedated (defined as at least 80% of
total time in target range); number with inappropriate
prolonged sedation; cost of sedation. Statistical analysis
was performed by Chi square with Yates correction and
the Mann-Whitney U test.
Patients were withdrawn from the study when they
reached one of the following points.
(1) Treatment failures: patients in whom it proved impos-
sible to maintain sedation within the target range with
the regimen to which they had been randomised.
(2) Change of target range: patients in whom a change in
clinical condition made maintenance of sedation in the
target range inappropriate. This included patients for
whom sedation was no longer indicated as mechanical
ventilation was to be weaned, and patients in whom
deteriorating respiratory function necessitated a
deeper level of sedation to ensure adequate ventila-
tion. In those patients being weaned from mechanical
ventilation, administration of sedation for both groups
was discontinued according to standard unit weaning
practice but could be recommenced should patient agi-
tation required it. Any sedation administered during
the weaning period was included in the record of total
sedation administered and sedation scoring was contin-
ued until weaning from mechanical ventilation was
successful.
(3) Death.
Exclusion criteria are given in Table 2.
In addition to recording of hourly sedation scores, the
amount of sedation and morphine administered during the
study period was recorded. Cost of drug use was calcu-
lated on the basis of the amount of drug administered to
the patient or discarded. The standard infusion regimen
for midazolam was to dilute 50mg midazolam in the
patient’s maintenance intravenous fluid to make a total
volume of 100ml. This was costed as 50mg midazolam
used regardless of the volume administered to the patient. 
Inappropriately prolonged sedation
Patients were classified as exhibiting inappropriately pro-
longed sedation if they had a continued requirement for
80 Critical Care 1999, Vol 3 No 3
Table 1
Modified Ramsay Sedation Score
0 Agitated
1 Awake, but tranquil and cooperative
2 Asleep, opens eyes to surroundings
3 Asleep, opens eyes to name
4 Asleep, opens eyes to physical stimulus*
5 Asleep, moves and reacts to physical stimulus* only
6 Unconscious or unrousable
*Stimulus, hand clap next to ear or moderate tap on forehead.endotracheal intubation or were unable to obey com-
mands once sedation was discontinued. If inappropriately
prolonged sedation was suspected the patient was given a
slow intravenous injection of 0.5mg flumazenil in 0.1mg
aliquots to determine if persisting benzodiazepine seda-
tion was the cause of depressed conscious level.
Results
Twenty patients were randomised to each group and a
total of 31 patients completed the study (17 in the mida-
zolam group and 14 in the diazepam group). Reasons for
failure to complete the study are given in Table 3. There
was no significant difference between the two groups in
the sex distribution, age, admission Acute Physiology
And Chronic Health Evaluation (APACHE) II score,
mortality, incidence of renal or hepatic impairment, or
dose of morphine per hour given during the study period
(Table 4). The results for the sedation endpoints are
given in Table 5. The only significant difference was an
increase in the percentage of hours undersedated in the
group treated with diazepam. Overall, 11 out of 17
patients treated with the midazolam regimen (64.7%)
were adequately sedated in comparison with five out of
14 (35.7%) treated with the diazepam regimen (odds ratio
3.33, 95% confidence interval 0.75–14.5, P=0.21) no
patient in either group exhibited inappropriately pro-
longed sedation attributable to benzodiazepine. One
patient known to have chronic liver impairment and
admitted to the ICU with sepsis exhibited prolonged
sedation despite receiving only 2.5mg diazepam.
However, there was no improvement in this patient’s
conscious level with flumazenil suggesting the prolonged
sedation was not due to benzodiazepine.
The number of hours of sedation, mean dose of drug
administered, and mean cost per patient and per hour of
sedation are given in Table 6.
Based on this study’s results, we determined that the fol-
lowing changes to our study protocol should be made to
conduct a larger study comparing an intermittent with
continuous sedation regimen.
Approximately 70 patients would need to be entered into
each limb of an unpaired case–control study with 1:1 ran-
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Table 2
Study exclusion criteria
Allergy to benzodiazepines or morphine
At risk of epilepsy
Intracranial hypertension
Admission diagnosis of drug overdose
Table 3
Reasons for randomised patients not completing study
Exclusion reason Midazolam Diazepam
Treatment failure* 1 1
No sedative given 1 4
Data incomplete 1 1
*Treatment failure defined as patient given other sedative during first
hour of study as not adequately sedated by regimen to which they had
been randomised.
Table 4
Patient demographics, analgesia, and incidence of renal and
hepatic impairment
Midazolam Diazepam
Number (% male) 17 (76.5%) 14 (64.3%)
Mean age (SD) 44.1 (17.7) 56.6 (16.8)
Median APACHE II (range) 17 (5–35) 15 (3–33)
Mortality (%) 1/17 (5.9%) 1/14 (7.1%)
Incidence of renal impairment 1/17 (5.9%) 2/14 (14.2%)
Incidence of hepatic impairment 0/17 (0%) 2/14 (14.2%)
Morphine (mg/h), median (range) 2.8 (0–6.6) 1.6 (0–4.5)




Hours to target 2 (0–39) 2 (0–22) NS*
Hours with target score (%) 85.0 (0–100) 59.2 (0–100) NS*
Hours undersedated (%) 0 (0–21) 21.1 (0–43) P = 0.01
Hours oversedated (%) 14.8 (0–100) 2.8 (0–97) NS*
Values are shown as median (range). *P > 0.05.
Table 6
Cost data for two sedation regimens
Midazolam Diazepam
Drug cost (AUS$/mg) 0.32 0.032
Mean hours of sedation per patient 46.5 39.4
Mean dose per patient 286mg 62mg
Average cost per patient AUS$92.24 AUS$2.07
Average cost per hour of sedation AUS$1.98 AUS$0.06domisation to demonstrate a significant difference in
quality of sedation.
The Ramsay sedation score should be further modified so
that patients who exhibited a short period of agitation
requiring either a single bolus of the continuous agent or a
single additional bolus of the intermittent agent were not
classified as undersedated.
Measures other than a sedation score should be used to
determine the quality of sedation in the ICU. They
should include a record of the need for physical restraints
to prevent patients removing endotracheal tubes or
intravascular lines. A record of the number of times endo-
tracheal tubes or intravascular lines were accidentally
removed by patients, along with the occurrence of poten-
tially harmful physiological abnormalities such as hyper-
tension, tachycardia, cardiac arrhythmias or intracranial
hypertension which were attributable to inadequate seda-
tion should be made. In the same regard, hypotension
attributable to the sedation regimen should be recorded.
Finally, and possibly most importantly, surviving patients
should be interviewed following discharge from the ICU
to determine their recollection of their time in ICU and
whether or not they found their stay in ICU painful or
mentally disturbing.
Discussion
Many drugs have been used to sedate critically ill patients
including intravenous anaesthetic agents [3,12–14], inhala-
tional anaesthetic agents [15–17], opiates [18,19], and bar-
biturates [20]. No drug can claim to be the ideal ICU
sedative, and benzodiazepines remain the most commonly
used [5,6]. In 1991, lorazepam, diazepam and midazolam
were used almost equally in the USA [5]. Most units gave
drugs intermittently although 36% used midazolam by
infusion. In 1987, midazolam and diazepam were used
approximately equally in the UK, but 65% of units pre-
ferred to give sedatives by continuous infusion [6]. Seda-
tion practice in Australian ICUs is not well documented.
In this randomised, controlled, pilot study, we have exam-
ined the two sedation regimens currently used in our ICU.
This study is not a comparison between two drugs, but
rather between two sedation regimens. Although intermit-
tent dosing was the preferred method in the USA [5],
most published studies have compared drugs being given
by continuous infusion. A computerized literature search
from 1963 to date revealed only one study comparing
intermittent and continuous regimens [21]. Intermittent
dosing imposes additional nursing work but makes accu-
mulation less likely, and inappropriately prolonged seda-
tion due to intermittent diazepam was not seen in this
study. Administration by continuous infusion is more con-
venient, may provided a more uniform level of sedation,
but risks greater drug use and accumulation if sedation
level is not closely monitored. Our study supports these
theoretical differences. Some of the results are inconclu-
sive due to the small sample size and the heterogeneity of
a general ICU population. Despite the similarity of the
patients, and the duration of sedation in the two groups,
more midazolam was administered and cost AUS$45.00
more per day. This cost may be justified if it results in
better patient outcomes, savings in staff costs [22], or
shorter ICU stays [3]. There was no difference in mortal-
ity between the groups, and this would not be expected in
a study of this size. There was higher rate of underseda-
tion apparent in the diazepam group, but this may be an
artefact as the scoring system used was not designed to
monitor intermittent dosing regimens, and patients had to
exhibit agitation to receive a bolus dose of diazepam.
Our recommendations for future sedation studies include
the use of measures other than the sedation score to evalu-
ate the adequacy of sedation. Studies conducted in our
unit suggest that patients surviving ICU are disturbed by
having no memory of that period of their life [23]. Thus,
what appears to medical and nursing staff to be an ideal
sedative agent, in particular more recently available short-
acting anaesthetic agents which provide titratable seda-
tion, but by nature of their very short duration of action
allow patients to be heavily sedated without the risk of
significant accumulation, may encourage staff to overse-
date patients. Despite the patients being ‘well-sedated’,
they may later be disturbed by having no memory whatso-
ever of their time in ICU. This is an area of ICU practice
that requires considerable further study.
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